The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
A 3-star rating suggests average performance compared to other similar companies.
The economic moat refers to the competitive advantage a company has over its competitors. A narrow moat suggests that the company has a less sustainable competitive advantage compared to those with wider moats.
This ratio indicates whether the stock is trading above (greater than 1) or below (less than 1) its fair value as determined by Morningstar's quantitative analysis. A ratio of 0.94 suggests the stock is currently trading at a slight discount (undervalued).
Extreme uncertainty in fair value estimates indicates exceptional potential volatility in the stock price. Investors should exercise caution and carefully assess their risk tolerance and investment strategy when considering stocks with this level of uncertainty.
These price estimates indicate the price levels at which Morningstar would consider the stock significantly overvalued (one-star) or undervalued (five-star) based on their analysis.
Moderate financial health suggests stability but also indicates potential risks. Evaluate the company's ability to manage its financial obligations and fund growth initiatives.
Valuation vs. Price: The stock is currently considered undervalued relative to its fair value, which could present a buying opportunity if you believe in Morningstar's valuation methodology.
Moat and Competitive Position: The narrow economic moat indicates less sustainable competitive advantages. Consider whether the company's business model and market position align with your investment goals.
Financial Health: Moderate financial health suggests stability but also indicates potential risks. Evaluate the company's ability to manage its financial obligations and fund growth initiatives.
Uncertainty: High uncertainty in fair value estimates implies potential volatility in the stock price. Factor in your risk tolerance and investment horizon when assessing this uncertainty.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
A former consultant to Cassava was indicted for alleged fraud related to NIH grants. Cassava received some federal funding related to these grants....
Cassava Sciences SAVA has engaged the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC) amid ongoing investigations into the company and two senior employees....
Shares of Cassava Sciences (NASDAQ: SAVA ), which has an Alzheimer's drug candidate called simufilam, fell 35% on June 28 and another 13% over the weekend. This move in SAVA stock comes after a key sc...
Shares of biotech company Cassava Sciences Inc. plummeted on Friday after a federal grand jury indicted a onetime science advisor to Cassava and charged him with falsifying data to obtain millions of ...
A federal indictment accuses a Cassava Sciences advisor of faking data to secure NIH grants. The company also faces shareholder suits....
AUSTIN, Texas, June 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), reported it has learned today that a federal grand jury returned an indictment charging Hoau-Yan Wang for alleg...
In 2024, the iShares Biotechnology ETF (NASDAQ: IBB ) is up just over 1.5%. If you're looking for steady, dividend-paying stocks, you can find a number of biotech stocks to buy from the holdings in t...
This week in Cheap Seats: Stocks Under $20 segment, we're taking a look at two stocks presenting an interesting buying opportunity: Cassava Sciences Inc (NASDAQ:SAVA) and Vale SA (NYSE:VALE)....
After reaching an important support level, Cassava Sciences, Inc. (SAVA) could be a good stock pick from a technical perspective. SAVA recently experienced a "golden cross" event, which saw its 50-day...